Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
- PMID: 10918187
Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
Abstract
Members of the c-erbB family have been implicated in poor prognosis in breast cancer. Given the propensity for heterodimerisation within the erbB family, the pattern of co-expression of these receptors is likely to be as functionally important as aberrant expression of any given receptor alone. Therefore, the patterns of expression of the receptors, epidermal growth factor receptor (EGF-R), c-erbB-2, c-erbB-3, c-erbB-4, and one of the erbB ligands, heregulin (HRG), were examined in normal and malignant breast cell lines and compared with expression of oestrogen receptor (ER), a classical indicator of good prognosis. There was an inverse correlation between ER and EGF-R mRNA levels, as previously described, but no correlation between either of these receptors and c-erbB-2. c-erbB-3 expression was positively correlated with ER. In contrast, HRG expression was inversely related to ER. Expression of antisense-ER resulted in increased EGF-R mRNA, demonstrating a functional link between the expression of these 2 genes, however, there was no significant change in c-erbB-2 or c-erbB-3 mRNA, suggesting that ER is not directly involved in control of expression of these genes. A comparison of individual erbB receptors and HRG revealed that the majority of lines expressing increased levels of c-erbB-2 also expressed elevated levels of c-erbB-3 mRNA, and none of the cell lines that expressed both c-erbB-2 and either c-erbB-3 or c-erbB-4 expressed the ligand HRG. In summary, the levels of expression of c-erbB-1, -2, -3, and -4 varied in this series of breast cell lines, and the pattern of expression and the relationship of each growth factor receptor to the expression of ER was quite distinct. The lack of expression of HRG in cell lines that express receptors may be indicative of paracrine interactions between erbB ligands and their cognate receptors and may suggest that the ligand and receptors are expressed in different subtypes of breast epithelial cells from which the cell lines are derived.
Copyright 2000 Wiley-Liss, Inc.
Similar articles
-
erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.Cancer Res. 1996 Feb 15;56(4):899-907. Cancer Res. 1996. PMID: 8631031
-
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.Cell Growth Differ. 1996 May;7(5):551-61. Cell Growth Differ. 1996. PMID: 8732665
-
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.Oncogene. 2000 Jul 20;19(31):3460-9. doi: 10.1038/sj.onc.1203685. Oncogene. 2000. PMID: 10918604
-
Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers.Int J Biol Markers. 2012 Jul 19;27(2):e111-7. doi: 10.5301/JBM.2012.9198. Int J Biol Markers. 2012. PMID: 22505232 Review.
-
The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.Trans Am Clin Climatol Assoc. 2003;114:315-33; discussion 333-4. Trans Am Clin Climatol Assoc. 2003. PMID: 12813928 Free PMC article. Review.
Cited by
-
DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care.Cancers (Basel). 2024 Apr 19;16(8):1573. doi: 10.3390/cancers16081573. Cancers (Basel). 2024. PMID: 38672654 Free PMC article. Review.
-
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs.Acta Pharmacol Sin. 2024 Apr;45(4):857-866. doi: 10.1038/s41401-023-01221-4. Epub 2024 Jan 10. Acta Pharmacol Sin. 2024. PMID: 38200149
-
HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel.Cancer Cell Int. 2023 Sep 16;23(1):204. doi: 10.1186/s12935-023-03055-w. Cancer Cell Int. 2023. PMID: 37716943 Free PMC article.
-
The production of the first functional antibody mimetic in higher plants: the chloroplast makes the DARPin G3 for HER2 imaging in oncology.Biol Res. 2022 Oct 23;55(1):32. doi: 10.1186/s40659-022-00400-7. Biol Res. 2022. PMID: 36274167 Free PMC article.
-
Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells.Biochem Biophys Rep. 2022 Aug 19;31:101326. doi: 10.1016/j.bbrep.2022.101326. eCollection 2022 Sep. Biochem Biophys Rep. 2022. PMID: 36039113 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous